Veterans Aging Cohort Study (VACS) 1.0 Index
ورودیهای بالینی بیمار
حداقل ۱۸ — حداکثر ۱۲۰ • واحد: years
حداقل ۰ — حداکثر ۵۰۰۰ • واحد: cells/mm³
حداقل ۰ — حداکثر ۱۰۰۰۰۰۰۰ • واحد: copies/mL
حداقل ۳ — حداکثر ۲۵ • واحد: g/dL
حداقل ۰ — حداکثر ۵۰ • واحد: index
حداقل ۰ — حداکثر ۲۰۰ • واحد: mL/min/1.73m²
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Low Risk0–20
- Moderate Risk21–40
- High Risk41–60
- Very High Risk61–150
The Veterans Aging Cohort Study (VACS) 1.0 Index calculates predicting invasive bacterial infection probability and quantifying systemic host response to sepsis. Key inputs include age. Scores guide administering empiric broad-spectrum antimicrobial regimens, infectious source control, and isolation protocols. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Estimates 5-year all-cause mortality risk in patients with HIV and/or HCV by integrating HIV-specific biomarkers (CD4 count, HIV-1 RNA) with general health indicators (hemoglobin, liver function, kidney function, and hepatitis C co-infection).
Clinical Indication
The Veterans Aging Cohort Study (VACS) 1.0 Index is indicated for bedside clinical practice to support Estimates 5-year all-cause mortality risk in patients with HIV and/or HCV by integrating HIV-specific biomarkers (CD4 count, HIV-1 RNA) with general health indicators (hemoglobin, liver function, kidney function, and hepatitis C co-infection).. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with suspected sepsis, meningitis, pneumonia, COVID-19, opportunistic infections, or fever of unknown origin. Clinical application is indicated across Infectious disease services, septic shock bays, febrile illness clinics, and isolation units.
Limitations & Contraindications
Timely administration of empiric antibiotic therapy in suspected septic shock must never be delayed for score tabulation.
Clinical Pearls & Action Plan
Blood and site-specific microbiological cultures should be secured prior to administering broad-spectrum antimicrobials.
VACS 1.0 Index = Age points + CD4 points + HIV RNA points + Hemoglobin points + FIB-4 points + eGFR points + HCV points Age: <50y=0, 50-64y=12, ≥65y=27 CD4: ≥500=0, 350-499=6, 200-349=6, 100-199=10, 50-99=28, <50=29 HIV RNA: <500=0, 500-99999=7, ≥100000=14 Hemoglobin: ≥14=0, 12-13.9=10, 10-11.9=22, <10=38 FIB-4: <1.45=0, 1.45-3.25=6, >3.25=25 eGFR: ≥60=0, 45-59.9=6, 30-44.9=8, <30=26 HCV: No=0, Yes=5
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| age | integer | Yes | Patient's age in years(years) |
| cd4_count | integer | Yes | CD4+ T cell count(cells/mm³) |
| hiv_rna_copies_ml | integer | Yes | HIV-1 RNA viral load(copies/mL) |
| hemoglobin_g_dl | float | Yes | Hemoglobin level(g/dL) |
| fib4_index | float | Yes | FIB-4 Index for liver fibrosis assessment (calculated using age, ALT, AST, and platelet count)(index) |
| egfr_ml_min | float | Yes | Estimated glomerular filtration rate (eGFR)(mL/min/1.73m²) |
| hepatitis_c_coinfection | string | Yes | Hepatitis C co-infection status |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–20 | Low Risk | Low 5-year mortality risk |
| 21–40 | Moderate Risk | Moderate 5-year mortality risk |
| 41–60 | High Risk | High 5-year mortality risk |
| 61–150 | Very High Risk | Very high 5-year mortality risk |
Evidence-Based References (EBM)
- Justice AC, McGinnis KA, Skanderson M, et al. Towards a combined prognostic index for survival in HIV infection: the role of 'non-HIV' biomarkers. HIV Med. 2010;11(2):143-151.
- Tate JP, Justice AC, Hughes MD, et al. An internationally generalizable risk index for mortality prediction in HIV-infected adults. AIDS. 2013;27(4):563-572.
- Justice AC, Dombrowski E, Conigliaro J, et al. Veterans Aging Cohort Study (VACS): Overview and description. Med Care. 2006;44(8 Suppl 2):S13-24.